News | December 20, 2022
Ipca acquires further 6.53% of equity share of Trophic Wellness
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Positive opinions based on significant survival benefit
EC grants conditional marketing authorization based on the EFFISAYIL trial
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Desonide Cream, 0.05%, has an estimated market size of US $12 million for twelve months ending Sep 2022 according to IQVIA
This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Subscribe To Our Newsletter & Stay Updated
